NASDAQ : GANX
Gain Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.13 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 49.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 49.32M |
| Enterprise Value | 36.84M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 43.64M |
| Shares Outstanding | 43.64M |
| Shares Change (YoY) | +39.34% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | 2.31% |
| Owned by Institutions (%) | 20.43% |
| Float | 42.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.34 |
| P/TBV Ratio | 4.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.36 |
| Quick Ratio | 4.11 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -268.30% |
| Return on Assets (ROA) | -95.51% |
| Return on Invested Capital (ROIC) | -148.18% |
| Return on Capital Employed (ROCE) | -160.97% |
| Weighted Average Cost of Capital (WACC) | 5.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$957,441 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 906,540 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -37.91% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 27.33 |
| Average Volume (20 Days) | 612,522 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.19M |
| Short Previous Month | 3.06M |
| Short % of Shares Out | 7.31% |
| Short % of Float | 7.49% |
| Short Ratio (days to cover) | 6.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -9.99M |
| Operating Income | -19.30M |
| Pretax Income | -19.20M |
| Net Income | -20.11M |
| EBITDA | -19.25M |
| EBIT | -19.30M |
| Earnings Per Share (EPS) | -$0.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 13.08M |
| Total Debt | 609,874 |
| Net Cash | 12.47M |
| Net Cash Per Share | $0.29 |
| Equity (Book Value) | 11.29M |
| Book Value Per Share | 0.26 |
| Working Capital | 11.54M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.95M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 49,531 |
| Net Borrowing | -100,843 |
| Free Cash Flow | -18.95M |
| FCF Per Share | -$0.43 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -39.34% |
| Shareholder Yield | -39.34% |
| Earnings Yield | -45.06% |
| FCF Yield | -38.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.20 |
| Price Target Difference | 537.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |